(Q33840974)

29 July 2017

1 reference

title

Cancer gene therapy: hard lessons and new courses (English)

1 reference

29 July 2017

0 references

1 reference

Vile RG

1

1 reference

29 July 2017

Russell SJ

series ordinal

2

1 reference

29 July 2017

Lemoine NR

series ordinal

3

1 reference

29 July 2017

language of work or name

1 reference

1 January 2000

1 reference

29 July 2017

1 reference

29 July 2017

7

1 reference

29 July 2017

2-8

1 reference

29 July 2017

1

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.gt.3301084

29 July 2017

0 references

cites work

Immunotherapy of malignancy by in vivo gene transfer into tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301084

Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301084

Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301084

Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: a pilot study in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301084

Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301084

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301084

Gene therapy -- promises, problems and prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301084

Paracrine cytokine adjuvants in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301084

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301084

PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301084

Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301084

Immune system in suicide-gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301084

Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301084

Systemic gene delivery expands the repertoire of effective antiangiogenic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301084

The bystander effect in the HSVtk/ganciclovir system and its relationship to gap junctional communication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301084

Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301084

A family of bicistronic vectors to enhance both local and systemic antitumor effects of HSVtk or cytokine expression in a murine melanoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301084

An innate sense of danger

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301084

Apoptosis or necrosis for tumor immunotherapy: what's in a name?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301084

Enhancement of tumor ablation by a selected HSV-1 thymidine kinase mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301084

Disabled infectious single-cycle herpes simplex virus as an oncolytic vector for immunotherapy of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301084

p53-dependent cell death/apoptosis is required for a productive adenovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301084

Reovirus therapy of tumors with activated Ras pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301084

Insulation of a conditionally expressed transgene in an adenoviral vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301084

Strategies for achieving multiple layers of selectivity in gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301084

Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301084

Somatic mutations in paroxysmal nocturnal hemoglobinuria: a blessing in disguise?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301084

Selective transduction of protease-rich tumors by matrix-metalloproteinase-targeted retroviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301084

Tumor-specific gene transfer via an adenoviral vector targeted to the pan-carcinoma antigen EpCAM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301084

Tumor targeting with a selective gelatinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301084

Progress in transcriptionally targeted and regulatable vectors for genetic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301084

Targeting angiogenesis: genetic intervention which strikes at the weak link of tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301084

Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301084

Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301084

Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301084

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301084

Human tumor antigens recognized by T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301084

Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301084

Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301084

Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301084

Dendritic cells and the control of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301084

Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301084

Immunotherapy III: Combinatorial molecular immunotherapy--a synthesis and suggestions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301084

Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301084

Cancer antigens: immune recognition of self and altered self

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301084

Tumor immunity as autoimmunity: tumor antigens include normal self proteins which stimulate anergic peripheral T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301084

Inducing autoimmune disease to treat cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301084

Gene therapy for cancer--managing expectations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301084

An adenovirus-Epstein-Barr virus hybrid vector that stably transforms cultured cells with high efficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301084

inferred from DOI database lookup

7 January 2021

based on heuristic

Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301084

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.GT.3301084

1 reference

Dimensions Publication ID

29 July 2017

0 references

1 reference